By: Sara Riascos  Feb. 28, 2022

Major Joint Replacement is frequently associated with hospital readmission. Readmission is a hospital quality measure that reflects dimensions of quality of inpatient care and also impacts overall programs by payers such as CMS’s Star Rating Program, HRRP and Value-Based Purchasing. XARELTO(Rivaroxaban) is a factor XA inhibitor prescribed by doctors to prevent blood clots from irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. Studies have shown that the early use of XARELTO(Rivaroxaban) after a Major joint replacement surgery is associated with decreased the rate of symptomatic VTE. Other studies have shown that XARELTO(Rivaroxaban) had a superior effect in THA patients. Dexur’s analysis of Real-World Evidence based on Medicare Claims data showed that the use of XARELTO(Rivaroxaban) within 7 days of hospitalization was associated with lower hospital readmission rates for Major Joint Replacement at Quail Creek Surgical Hospital, in AMARILLO, TX, 79124. Reduction in readmission rates helps hospitals improve their outcomes for various cost and quality programs. Dexur is an approved entity to perform Medicare claims data analysis, which it uses to perform quality outcomes analysis. Dexur has published several papers with Harvard Medical School on quality outcomes related topics. Dexur’s analysis of Drugs and their impact on quality outcomes, such as readmissions and mortality, are used by Hospitals, IDNs, and ACOs to implement best practices and manage Real World Evidence based risk factors.

By: Neha Thomas  Jul. 16, 2020

Dexur’s analysis of medicare claims of hospitals within a 10-mile radius of Flint, Michigan, showed that McLaren Flint, Ascension Genesys Hospital, and Hurley Medical Center had the best value outcomes over a 90 day episode for Sepsis. Dexur’s value analysis tracks a patient’s episode of care from the date of admission for 90 days and includes the index hospitalizations, rehospitalization, home health, nursing home, and ED costs. Total cost of care data helps patients make appropriate choices and helps local ACOs, such as PMC ACO, GGC ACO, LLC, and Genesys PHO, L.L.C., make appropriate referral choices. The analysis was risk-adjusted, for alive and non-hospice patients and was done at the DRG level, specifically DRG 871: Septicemia or Severe Sepsis without MV >96 Hours with Major Complication or Comorbidity, to adjust for complications and comorbidities.